Table 1 Baseline characteristics of patients enrolled in a pilot treatment program for chronic hepatitis B, Addis Ababa, Ethiopia
All patients (n = 1303) | Eligible for treatment (n = 328) | Not eligible for treatment (n = 962)a | ||
|---|---|---|---|---|
Number (%) | Number (%) | Number (%) | P | |
Men | 770 (59.1) | 260 (79.3) | 500 (52.0) | < 0.001 |
Age (years) | 0.006 | |||
18–25 | 286 (21.9) | 64 (19.5) | 220 (22.9) | |
26–35 | 549 (42.1) | 122 (37.2) | 424 (44.1) | |
36–45 | 289 (22.2) | 83 (25.3) | 202 (21.0) | |
> 45 | 179 (13.7) | 59 (18.0) | 116 (12.1) | |
Marital status | 0.667 | |||
Single | 457 (35.1) | 117 (35.7) | 338 (35.1) | |
Married | 796 (61.1) | 201 (61.3) | 584 (60.7) | |
Divorced/widowed | 50 (3.8) | 10 (3.0) | 40 (4.2) | |
ALT, U/Lb | < 0.001 | |||
< 40 | 1014 (78.9) | 185 (57.3) | 818 (86.2) | |
40–79 | 201 (15.6) | 91 (28.2) | 108 (11.4) | |
≥ 80 | 70 (5.4) | 47 (14.6) | 23 (2.4) | |
HBV viral load, IU/mLc | < 0.001 | |||
< 2000 | 722 (56.5) | 107 (33.1) | 608 (64.5) | |
2000–19,999 | 256 (20.0) | 46 (14.2) | 208 (22.1) | |
≥ 20,000 | 301 (23.5) | 170 (52.6) | 127 (13.5) | |
Transient elastography, kPad | < 0.001 | |||
< 8.0 | 879 (74.0) | 46 (15.0) | 825 (94.5) | |
8.0–9.9 | 67 (5.6) | 39 (12.7) | 27 (3.1) | |
≥ 10.0 | 242 (20.4) | 221 (72.2) | 21 (2.4) | |
Co-infections | ||||
Anti-HCV positive | 28 (2.1) | 7 (3.2) | 21 (2.6) | 0.619 |
Anti-HDV positive | 19 (1.4) | 10 (5.9) | 9 (1.0) | < 0.001 |
APRI, median (IQR)e | 0.24 (0.17–0.36) | 0.48 (0.27–0.90) | 0.21 (0.16–0.29) | < 0.001 |
FIB-4, median (IQR)f | 0.56 (0.41–0.79) | 1.06 (0.61–1.91) | 0.55 (0.41–0.76) | < 0.001 |